Introduction
- Characterized by premature red blood cell destruction exceeding bone marrow production capacity.
- Shortened survival mediated directly by autoantibodies targeting red cell membrane antigens, with or without complement participation.
Classification and Etiology
- Categorized primarily by antibody thermal amplitude and optimal binding temperature.
- Classified as primary (idiopathic) or secondary to underlying systemic processes.
| Classification | Antibody type | Optimal binding temperature | Underlying associations |
|---|---|---|---|
| Warm | Immunoglobulin G | 37°C | Idiopathic, systemic lupus erythematosus, immunodeficiencies, autoimmune lymphoproliferative syndrome, lymphoma. |
| Cold agglutinin disease | Immunoglobulin M | Less than 37°C | Idiopathic, Mycoplasma pneumoniae, Epstein-Barr virus, cytomegalovirus, lymphoproliferative disorders. |
| Paroxysmal cold hemoglobinuria | Immunoglobulin G (Donath-Landsteiner) | Binds in cold, lyses at 37°C | Nonspecific viral infections, congenital or tertiary syphilis (historically). |
| Drug-induced | Hapten or immune complex | Variable | Cephalosporins, penicillins, quinine, quinidine, methyldopa, checkpoint inhibitors. |
Pathophysiology
Tolerance Loss
- Underpinned by loss of central and peripheral self-tolerance.
- Autoreactive B lymphocytes synthesize anti-red cell autoantibodies, supported by T helper lymphocytes.
- Molecular mimicry alters red cell membrane antigenicity, inciting inappropriate immune responses.
Warm Antibody Mechanisms
- Immunoglobulin G autoantibodies target "public" antigens, most commonly Rh proteins.
- Antibody-coated red cells undergo extravascular hemolysis.
- Splenic macrophages identify Fc regions, phagocytosing and destroying affected erythrocytes.
- Massive immunoglobulin G quantities occasionally fix complement, triggering intravascular hemolysis.
Cold Antibody Mechanisms
- Immunoglobulin M autoantibodies target I/i system oligosaccharide antigens.
- Anti-I specificity frequently associates with Mycoplasma pneumoniae.
- Anti-i specificity frequently associates with infectious mononucleosis.
- Immunoglobulin M activates complement efficiently; induces intravascular complement-mediated lysis or extravascular hepatic/splenic destruction.
Paroxysmal Cold Hemoglobinuria
- Donath-Landsteiner immunoglobulin G autoantibody exhibits anti-P specificity.
- Binds red cells in cold extremities.
- Activates complement cascade leading to massive intravascular lysis upon rewarming to 37°C.
Drug-Induced Mechanisms
- Hapten mechanism: drug binds red cell membrane tightly; antibodies target drug molecules leading to splenic destruction (e.g., penicillin).
- Ternary complex: drug, membrane antigen, and antibody form complex (e.g., quinine).
- True autoantibody induction: drug incites autoantibodies without requiring ongoing drug presence (e.g., methyldopa).
Clinical Manifestations
- Onset sudden or gradual.
- Pallor, fatigue, shortness of breath, dizziness prominent.
- Jaundice, scleral icterus, dark urine (hemoglobinuria) present.
- Splenomegaly typically noted.
- Cardiovascular compromise rare but life-threatening.
- Acrocyanosis or extremity agglutination seen in cold antibody disease upon cold exposure.
- Concurrent immune thrombocytopenic purpura defines Evans syndrome.
Laboratory Investigations
Hematologic Parameters
- Hemoglobin severely reduced, often dropping below 6 g/dl.
- Reticulocytosis prominent, reflecting compensatory marrow hyperplasia.
- Reticulocytopenia occasionally observed due to autoantibody targeting marrow precursors, parvovirus infection, or "shocked" marrow.
- Leukocytosis frequently present.
- Platelet count normal, unless concurrent Evans syndrome exists.
Peripheral Smear Morphology
- Spherocytes abundant due to macrophage-mediated partial membrane loss.
- Polychromasia indicates reticulocyte response.
- Nucleated red blood cells visible.
- Erythrophagocytosis occasionally noted.
- Autoagglutination or rouleaux formation characterizes cold antibody disease.
Biochemical Markers
- Unconjugated bilirubin markedly elevated.
- Lactate dehydrogenase significantly increased.
- Serum haptoglobin severely decreased.
- Hemoglobinuria and hemosiderinuria present in intravascular hemolysis.
Diagnostic Testing
| Test modality | Warm antibody | Cold antibody | Paroxysmal cold hemoglobinuria |
|---|---|---|---|
| Direct antiglobulin test | Positive for immunoglobulin G and/or C3 | Positive for C3 only | Positive for C3 only |
| Indirect antiglobulin test | Often positive (free antibody) | Positive | Negative conventionally |
| Specific assays | Eluate reacts with all test cells (panagglutinin) | Cold agglutinin titer high at <37°C | Donath-Landsteiner test positive |
- Direct antiglobulin test rarely negative.
- Negative direct antiglobulin test requires reference laboratory testing for immunoglobulin A, low-affinity antibodies, or natural killer cell-mediated hemolysis.
Differential Diagnosis
| Condition | Distinguishing features |
|---|---|
| Isoimmune hemolytic disease | Neonatal onset, maternal-fetal ABO/Rh incompatibility, positive direct antiglobulin test. |
| Hereditary spherocytosis | Family history, negative direct antiglobulin test, positive eosin-5-maleimide binding flow cytometry. |
| Microangiopathic hemolytic anemia | Schistocytes, helmet cells, negative direct antiglobulin test, renal/neurologic involvement. |
| Glucose-6-phosphate dehydrogenase deficiency | Bite cells, Heinz bodies, oxidant exposure history, negative direct antiglobulin test. |
| Wilson disease | Negative direct antiglobulin test, liver/central nervous system involvement, high copper. |
Management
Warm Autoimmune Hemolytic Anemia
- Blood transfusion: utilize "least incompatible" blood. Administer small volumes (5 ml/kg) slowly (2 ml/kg/h) to prevent cardiopulmonary embarrassment. Coordinate closely with blood bank.
- Glucocorticoids: first-line therapy. Administer intravenous methylprednisolone (1-2 mg/kg/day, up to 30 mg/kg daily for 3 days in severe cases) or oral prednisone (2 mg/kg/day). Taper slowly over 4-6 months once hemoglobin stabilizes.
- Intravenous immunoglobulin: 0.8-1.0 g/kg/day or up to 5 g/kg total. Response often poor in children; reserved for severe refractory hemolysis.
- Rituximab: 375 mg/m2 weekly for 4 weeks. Highly effective for steroid-refractory or steroid-dependent cases.
- Plasmapheresis: limited efficacy because immunoglobulin G resides primarily in extravascular spaces.
- Immunomodulators: utilized for chronic or refractory management. Options include mycophenolate mofetil (15 mg/kg twice daily), sirolimus (specifically effective in autoimmune lymphoproliferative syndrome and Evans syndrome), cyclosporine, azathioprine, danazol, or bortezomib.
- Splenectomy: considered for severe refractory cases unresponsive to medical management. Requires preoperative immunization against encapsulated organisms and lifelong postoperative penicillin prophylaxis. Carries risks of thrombosis and pulmonary hypertension.
- Recombinant erythropoietin: indicated strictly for refractory cases manifesting severe reticulocytopenia.
Cold Agglutinin Disease
- Environmental control: maintain strict warmth; avoid cold exposure.
- Transfusion: utilize efficient in-line blood warmer strictly at 37°C. Unmonitored heating is dangerous.
- Plasmapheresis: highly efficient due to intravascular immunoglobulin M location.
- Rituximab: effective B-lymphocyte depleting agent for chronic or refractory cases.
- Glucocorticoids and splenectomy: marginally effective; generally not recommended.
Paroxysmal Cold Hemoglobinuria
- Self-limited course; typically resolves fully in 6-8 weeks.
- Environmental control: maintain warm environment.
- Transfusion: administer warmed blood for severe symptomatic anemia.
- Plasmapheresis or rituximab: reserved exclusively for rare chronic or relapsing cases.
Giant Cell Hepatitis Variant
- Rare distinct entity presenting aged 6-24 months.
- Presents with direct antiglobulin test-positive immune hemolysis, fever, and progressive liver failure.
- Requires intensive combined immunosuppression (corticosteroids, cyclophosphamide, rituximab, azathioprine).